Inhibition of HIV budding by a genetically selected cyclic peptide targeting the Gag-TSG101 interaction.
about
HIV type 1 Gag as a target for antiviral therapy"Splicing up" drug discovery. Cell-based expression and screening of genetically-encoded libraries of backbone-cyclized polypeptidesVirus maturation as a new HIV-1 therapeutic targetCyclic and Macrocyclic Peptides as Chemical Tools To Recognise Protein Surfaces and Probe Protein-Protein InteractionsCrystallographic and Functional Analysis of the ESCRT-I /HIV-1 Gag PTAP InteractionTherapeutic targets for the treatment of hepatitis E virus infectionSynthesis of macrocyclic organo-peptide hybrids from ribosomal polypeptide precursors via CuAAC-/hydrazide-mediated cyclizationCalcium Regulation of Hemorrhagic Fever Virus Budding: Mechanistic Implications for Host-Oriented Therapeutic InterventionSynthetic genomics and synthetic biology applications between hopes and concernsSolution structure of the ESCRT-I complex by small-angle X-ray scattering, EPR, and FRET spectroscopy.Rapid selection of cyclic peptides that reduce alpha-synuclein toxicity in yeast and animal modelsSynthetic biology approaches in drug discovery and pharmaceutical biotechnology.Novel approaches to inhibiting HIV-1 replication.Application of ring-closing metathesis macrocyclization to the development of Tsg101-binding antagonists.Targeting Bacillus anthracis toxicity with a genetically selected inhibitor of the PA/CMG2 protein-protein interactionEvolution of cyclic peptide protease inhibitors.Mechanistic studies on the substrate-tolerant lanthipeptide synthetase ProcMDiversity in genetic in vivo methods for protein-protein interaction studies: from the yeast two-hybrid system to the mammalian split-luciferase system.Targeting tumour proliferation with a small-molecule inhibitor of AICAR transformylase homodimerizationA bidirectional fluorescent two-hybrid system for monitoring protein-protein interactions.A cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells.Screening bicyclic peptide libraries for protein-protein interaction inhibitors: discovery of a tumor necrosis factor-α antagonistCyclic peptides as therapeutic agents and biochemical tools.Small-molecule probes targeting the viral PPxY-host Nedd4 interface block egress of a broad range of RNA viruses.Proline-rich regions and motifs in trafficking: from ESCRT interaction to viral exploitation.Peptides come round: using SICLOPPS libraries for early stage drug discovery.Methods for the creation of cyclic Peptide libraries for use in lead discovery.Ribosomal Synthesis of Macrocyclic Peptides in Vitro and in Vivo Mediated by Genetically Encoded Aminothiol Unnatural Amino AcidsHIV-1 Gag as an Antiviral Target: Development of Assembly and Maturation Inhibitors.Human genetic variation altering anthrax toxin sensitivity.Biological activities of natural and engineered cyclotides, a novel molecular scaffold for peptide-based therapeutics.Ribosomal Synthesis of Natural-Product-Like Bicyclic Peptides in Escherichia coli.Replacement of the hepatitis E virus ORF3 protein PxxP motif with heterologous late domain motifs affects virus release via interaction with TSG101Split Inteins: Nature's Protein Ligases.Side-chain-to-tail cyclization of ribosomally derived peptides promoted by aryl and alkyl amino-functionalized unnatural amino acidsInteins: Nature's Gift to Protein Chemists.Targeting the protein-protein interactions of the HIV lifecycle.Ribosomal synthesis of backbone macrocyclic peptides.Modulating protein-protein interactions: the potential of peptides.Interactions of HIV-1 proteins as targets for developing anti-HIV-1 peptides.
P2860
Q24614498-825CDF89-B74E-4AA3-981F-74C1CC1C6A63Q24634502-A895D3E4-66CD-4052-835F-1868353947CAQ24642446-BE33B215-A3AB-46A5-881C-7CC19AEA1DDBQ26777298-6F229B6B-42D9-48A1-8C67-895D47078F78Q27665841-242F2D4B-EEB2-481D-9E3F-988D25FA5B2AQ28084036-7B3E56DC-5A1A-4AE7-A4A1-2ABC38E303F6Q28084617-E7F96E2F-1C08-44A5-8E7E-FD849D3DCB8AQ28550701-A85992D2-7FA8-41D2-9456-3C5995FDBD07Q28706666-B540F1D4-0192-450E-8D1A-7DCC45940795Q30429357-86E601D0-39E5-4177-B117-61BF56220A51Q33481617-C48681B2-6ACF-412D-A484-776BD7CDDC60Q33557182-634607CA-BAF7-4A59-BFF0-B7672B12C715Q33624690-F74FA558-FA2F-4DDE-A2AD-BA8E03619946Q33638005-7A237F98-26AA-437D-8529-284636951B2AQ33780004-09E39D6C-EF4F-46DF-AE61-013FE3A72AFEQ33937777-3D25B690-CBC2-4AC2-8CFA-4F2374851BE2Q33951197-0180FD7D-B504-4F28-B4AF-4DDC0C38CF24Q34280594-45A12B88-996A-4E86-9EEC-4CCFAB1D674EQ34327238-91985464-D7F8-4A78-9C12-2A70A6C7E111Q34395186-F0FFF289-420E-4AF0-BDF5-2A10A79E9489Q34782024-F2F30269-342A-4F75-AE0E-7EED0356FFD4Q34832185-9A31AE26-D642-4211-B257-3E7EC41B3797Q35015231-CB41B481-5942-4861-ACC2-7D7226F41A93Q35150964-55703D10-82B4-4FB9-BCE7-289DEE6BDC69Q35173120-B3B027C1-B7A5-4D3D-BB99-930F7FB667EEQ35209857-7BF60AD2-C79C-445D-B428-C63A4DD3904AQ35542409-A41C32F2-96BC-4296-B7F1-084D11A5B4A4Q35620228-DBAA72C8-C4E8-4273-BFFF-BA32BAC7FB57Q35761626-044A4F3A-8068-4054-8D09-9D95755E5CAFQ35779094-C9356A8C-4222-494E-AE21-3C30FD617CDEQ35893500-3A997770-9C9F-467A-AEEB-BF8211020C7BQ36070579-C7DBEECE-3F01-4260-8A24-287EE603C5F4Q36373043-EAD8C1B7-AD9D-40F1-9F42-08D2F93DC40BQ36787669-12BF045B-96A8-4A57-9B98-DBD559E61E01Q37008853-D13DCA5B-C973-464D-9D66-FD5A92F1EFB3Q37630472-268C1193-3BFE-4E7D-876D-4960F4A52B64Q37820252-DD524B3E-2A48-428B-B159-E94D18EF8A5EQ37902087-943A5448-4C4B-4BDE-85FE-49F32DD8C267Q38314370-07AA619D-893B-454F-AF35-D183BCA8BD99Q38524164-34AC8068-A283-4429-9CCA-78865906A41E
P2860
Inhibition of HIV budding by a genetically selected cyclic peptide targeting the Gag-TSG101 interaction.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Inhibition of HIV budding by a ...... ng the Gag-TSG101 interaction.
@en
Inhibition of HIV budding by a ...... ng the Gag-TSG101 interaction.
@nl
type
label
Inhibition of HIV budding by a ...... ng the Gag-TSG101 interaction.
@en
Inhibition of HIV budding by a ...... ng the Gag-TSG101 interaction.
@nl
prefLabel
Inhibition of HIV budding by a ...... ng the Gag-TSG101 interaction.
@en
Inhibition of HIV budding by a ...... ng the Gag-TSG101 interaction.
@nl
P2093
P356
P1433
P1476
Inhibition of HIV budding by a ...... ng the Gag-TSG101 interaction.
@en
P2093
Jongsik Gam
Stanley N Cohen
Stephen J Benkovic
P304
P356
10.1021/CB800193N
P577
2008-12-01T00:00:00Z